Next Issue
Volume 40, IOCAB 2025
Previous Issue
Volume 38, IOCD 2025
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medical Sciences Forum
Volume 39
Issue 1
msf-logo

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Med. Sci. Forum, 2025, IKCSEU 2025

The 2025 International Kidney Cancer Symposium

Amsterdam, The Netherlands | 1–3 May 2025

Volume Editors:
Axel Bex, The Netherlands Cancer Institute, The Netherlands
Ignacio Durán, Hospital Universitario Marqués de Valdecilla, Spain
Salvatore La Rosa, Kidney Cancer Association, USA
Lisa Pickering, Royal Marsden Hospital, UK

Number of Papers: 4
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image): The 2025 International Kidney Cancer Symposium—Europe (IKCSEU25) was held in Amsterdam, The Netherlands, on 1–3 May 2025, organized by the Kidney Cancer Association (KCA). This annual [...] Read more.
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

5 pages, 170 KB  
Proceeding Paper
Shaping AI-Based Decision Support in Kidney Cancer: Multidisciplinary Consensus from the IKCSEU25 ART Think Tank
by Ignacio Duran and Jesus Garcia-Donas
Med. Sci. Forum 2025, 39(1), 1; https://doi.org/10.3390/msf2025039001 - 6 Nov 2025
Viewed by 706
Abstract
Background: Artificial intelligence (AI) has the potential to significantly enhance clinical decision-making in oncology. However, its application in renal cell carcinoma (RCC) remains limited. The ART (Artificial Intelligence in Renal Tumors) project is a Spanish, multi-institutional initiative aimed at developing a dynamic, [...] Read more.
Background: Artificial intelligence (AI) has the potential to significantly enhance clinical decision-making in oncology. However, its application in renal cell carcinoma (RCC) remains limited. The ART (Artificial Intelligence in Renal Tumors) project is a Spanish, multi-institutional initiative aimed at developing a dynamic, transcriptomics-based AI model to guide systemic treatment decisions for patients with metastatic RCC (mRCC). Objective: The aim of this paper is to present the rationale, methodology, and early implementation challenges of the ART project, as discussed during a dedicated Think Tank session at the 2025 International Kidney Cancer Symposium Europe (IKCSEU25), and to gather expert insights on its clinical and regulatory viability. Design, Setting, and Participants: The ART project includes three phases: (1) retrospective algorithm training using clinical and transcriptomic data from completed trials; (2) a prospective, non-interventional study collecting multi-omic and clinical data from 500 patients across 30 centers; and (3) a future comparative analysis of ART-guided versus standard clinical decisions. The AI model is designed to evolve continuously through ongoing data integration. Results and Limitations: Experts underscored the importance of integrating multimodal data—including circulating biomarkers and immune profiling—while expressing concerns about the reliance on short-term endpoints. Key barriers identified included data harmonization, external validation, and regulatory uncertainty regarding adaptive algorithms. The absence of a clear approval pathway for non-static clinical decision support systems also poses a challenge. Despite limited initial funding, the ART platform has generated strong institutional engagement and may serve as a scalable model for clinician-oriented AI tools. Conclusions: The ART project represents an innovative approach to AI-driven personalization of kidney cancer treatment. Expert feedback from IKCSEU25 highlighted the scientific robustness of the initiative, while also emphasizing the need for broader validation, regulatory clarity, and the use of clinically meaningful endpoints to support real-world implementation. Patient Summary: Experts reviewed a new AI-based tool being developed in Spain to help doctors choose the best treatments for kidney cancer. The tool shows promise but needs further testing and must meet regulatory standards before it can be used in routine clinical care. Full article
(This article belongs to the Proceedings of The 2025 International Kidney Cancer Symposium)
10 pages, 631 KB  
Proceeding Paper
First Interim Analysis of the CABONEXT Study: A Retrospective Evaluation of Treatment Patterns Following Cabozantinib Treatment for Advanced Renal Cancer
by Simon Nannini, Fabien Moinard-Butot, Sylvain Ladoire, Dorian Bochaton, Pierre Bigot, Félix Lefort, Hakim Mahammedi, Fabien Calcagno, Jean-Baptiste Barbe Richaud, Luca Campedel, Sabrina Falkowski, Karim Amrane, Haris Charalambous, Pierre Cornillon and Philippe Barthélémy
Med. Sci. Forum 2025, 39(1), 2; https://doi.org/10.3390/msf2025039002 - 13 Nov 2025
Viewed by 794
Abstract
The CABONEXT study is the first multicenter retrospective analysis evaluating subsequent systemic therapies after cabozantinib-based treatment in metastatic renal cell carcinoma (mRCC). This interim analysis includes 77 patients receiving subsequent treatments across two cohorts: after cabozantinib–nivolumab first-line treatment (Group A) and after ICI-based [...] Read more.
The CABONEXT study is the first multicenter retrospective analysis evaluating subsequent systemic therapies after cabozantinib-based treatment in metastatic renal cell carcinoma (mRCC). This interim analysis includes 77 patients receiving subsequent treatments across two cohorts: after cabozantinib–nivolumab first-line treatment (Group A) and after ICI-based first-line treatment followed by cabozantinib (Group B). Time to subsequent treatment failure (TTF) and disease control rate (DCR) remain higher in Group A with a median TTF of 5 months (vs. 3.4 months in Group B) and a DCR of 86% (vs. 48%). Second-generation TKIs, mostly axitinib or lenvatinib, seemed to be the best option in Group B compared to other treatments including everolimus or first-generation TKIs (HR = 3.82, 95%CI [1.64; 8.93], p = 0.1). These findings already emphasize the need for innovative therapies targeting resistance mechanisms and optimal treatment sequences. Along with ongoing accrual, further analyses are expected. Full article
(This article belongs to the Proceedings of The 2025 International Kidney Cancer Symposium)
►▼ Show Figures

Figure 1

5 pages, 303 KB  
Proceeding Paper
The Importance of Multidisciplinary Team Meetings (MDMs) with Focus on Minimal Surgery
by Lars Lund, Else Helene Ibfelt, Heidi Larsson, Niels Fristrup, Anne Kirstine Møller Darras and Mette Nørgaard
Med. Sci. Forum 2025, 39(1), 3; https://doi.org/10.3390/msf2025039003 - 17 Nov 2025
Viewed by 566
Abstract
Since 2010, all Danish departments treating renal cell carcinoma (RCC) have reported to the national quality database, enabling systematic auditing of outcomes. Using the unique Civil Registration Number, data are linked to national registries, ensuring comprehensive capture of diagnostics and treatments. The RCC [...] Read more.
Since 2010, all Danish departments treating renal cell carcinoma (RCC) have reported to the national quality database, enabling systematic auditing of outcomes. Using the unique Civil Registration Number, data are linked to national registries, ensuring comprehensive capture of diagnostics and treatments. The RCC database, established in August 2010, now includes over 13,000 cases, with 1035 new cases registered between August 2023 and July 2024. In this period, 939 patients underwent surgery or ablation, 54% with kidney-preserving procedures. Among nephrectomies, 85% were minimally invasive. Data-driven quality monitoring and multidisciplinary collaboration have contributed to standardized care and internationally comparable survival outcomes. Full article
(This article belongs to the Proceedings of The 2025 International Kidney Cancer Symposium)
►▼ Show Figures

Figure 1

44 pages, 2765 KB  
Conference Report
Abstracts of the 2025 International Kidney Cancer Symposium (IKCS) Europe
by Axel Bex, Ignacio Durán, Salvatore La Rosa and Lisa Pickering
Med. Sci. Forum 2025, 39(1), 4; https://doi.org/10.3390/msf2025039004 - 27 Nov 2025
Viewed by 1225
Abstract
The 2025 International Kidney Cancer Symposium—Europe (IKCSEU25) was held in Amsterdam, the Netherlands, from 1 to 3 May 2025, organized by the Kidney Cancer Association (KCA). This annual event serves as the premier European meeting dedicated to kidney cancer research and clinical innovation, [...] Read more.
The 2025 International Kidney Cancer Symposium—Europe (IKCSEU25) was held in Amsterdam, the Netherlands, from 1 to 3 May 2025, organized by the Kidney Cancer Association (KCA). This annual event serves as the premier European meeting dedicated to kidney cancer research and clinical innovation, fostering collaboration across academia, industry, and advocacy. Full article
(This article belongs to the Proceedings of The 2025 International Kidney Cancer Symposium)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Previous Issue
Next Issue
Back to TopTop